您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Taurolidine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Taurolidine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Taurolidine图片
CAS NO:19388-87-5
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议

产品介绍
Taurolidine 是一种广谱抗菌药物,用于预防中心静脉导管相关感染。
Cas No.19388-87-5
别名牛磺罗定
化学名4,4'-methylenebis(tetrahydro-1,2H,4-thiadiazine) 1,1,1',1'-tetraoxide
Canonical SMILESO=S1(CCN(CN2CNS(CC2)(=O)=O)CN1)=O
分子式C7H16N4O4S2
分子量284.4
溶解度≤10mg/ml in DMSO;10mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 9.6-34.2 microM for several cancer cell lines

Taurolidine is a synthetic taurine analog with antimicrobial and anti-neoplastic actions.

Taurine, a conditionally-essential amino acid, is not utilized in protein synthesis, but is found free or in simple peptides. Taurine has been shown to be essential in mammalian development. In vitro studies have demonstrated that low levels of taurine are associated with various pathological lesions.

In vitro: Previous study found that in selected human and murine tumor cell lines, a 3-day exposure to taurolidine could inhibit the growth of all of the cell lines. Further mechanistic study showed that in NIH-3T3 murine fibroblasts and the PA-1 and SKOV-3 human ovarian tumor cells, a 48-h exposure to taurolidine had little effect on cell cycle distribution in PA-1 and SKOV-3 cells but greatly increased the appearance of DNA debris, an effect consistent with an induction of apoptosis. In contrast, in NIH-3T3 cells, taurolidine exposure did not increase DNA debris in the sub-G(0)/G(1) region [1].

In vivo: Animal study found that the i.v. administration of 2% taurolidine and 3% taurolidine as well the i.p. application of 2% taurolidine could decrease the development of advanced i.p. tumor lesions. No changes of differential blood count nor relevant animal weight changes resulted. Moreover, taurolidine did not impair the liver tissue, kidneys, SVC, and leucopoiesis. The intravenous therapy of 2% taurolidine was found to be safe and anti-tumorigenic in advanced local tumor growth in rats [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Calabresi, P. ,Goulette, F.A. and Darnowski, J.W. Taurolidine: Cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Research 61(18), 6816-6821 (2001).
[2] Braumann C, Stuhldreier B, Bobrich E, Menenakos C, Rogalla S, Jacobi CA. High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats. J Surg Res. 2005 Nov;129(1):129-35.